<DOC>
	<DOCNO>NCT02972034</DOCNO>
	<brief_summary>This study evaluate safety , tolerability preliminary efficacy MK-8353 administer combination pembrolizumab ( MK-3475 ) . There two part study : Part 1 dose escalation confirmation , Part 2 cohort expansion . In Part 1 , recommend phase II dose ( RP2D ) MK-8353 combination fix dose pembrolizumab participant advance malignancy identify confirm . Participants initially enrol receive MK-8353 350 mg twice day ( BID ) combination pembrolizumab fix dose 200 mg Day 1 3-week cycle ( Q3W ) 24 month treatment . In Part 2 , participant advance colorectal cancer ( CRC ) receive least one five prior line therapy enrol RP2D expansion cohort evaluate safety efficacy .</brief_summary>
	<brief_title>Study MK-8353 Combination With Pembrolizumab ( MK-3475 ) Participants With Advanced Malignancies ( MK-8353-013 )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Part 1 : Has histologically cytologicallydocumented , locallyadvanced metastatic solid malignancy receive ≥1 &lt; 6 prior line cancer treatment regimen ( ) . Part 2 : Has histologicallyconfirmed adenocarcinoma originate colon rectum ( Stage 4 American Joint Committee Cancer [ AJCC ] 7th edition ) . Appendiceal cancer include . AND Has experience disease progression intolerant ≥1 &lt; 6 systemic chemotherapy regimen ( ) metastatic CRC must include fluoropyrimidines , irinotecan , oxaliplatin , +/ antivascular endothelial growth factor ( VEGF ) antiepidermal growth factor receptor ( EGFR ) ( indicate RAS mutational status ) . Provides archival newly obtain tumor tissue sample blood sample biomarker analysis . Has ≥1 measurable lesion define RECIST 1.1 image study . Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Has adequate organ function Female participant childbearing potential willing use either 2 adequate barrier method , abstain heterosexual activity throughout study . Male participant childbearing potential must agree use adequate method contraception . Has disease suitable local treatment administer curative intent . Part 1 : Has receive prior therapy cancer vaccine , compound target program cell death ligand 1 ( PDL1 ) , PDL2 , cytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) , Mitogenactivated protein kinase ( MAPK ) /Extracellular signalregulated Kinase ( MEK ) . Part 2 : Has receive prior therapy cancer vaccine , compound target PD1 ( include Merck pembrolizumab [ MK3475 ] ) , PDL1 , PDL2 , CTLA4 , lymphocyteactivation gene 3 ( LAG3 ) , CD137 , OX40 ( tumor necrosis factor receptor superfamily , member 4 [ TNFRSF4 ] , also know CD134 ) , cluster differentiation 40 ( CD40 ) , glucocorticoidinduced TNFRrelated protein ( GITR ) , serine/threonineprotein kinase BRaf ( BRAF ) , MEK molecules MAPK pathway . Is currently participate participate study investigational agent use investigational device within 4 week prior first dose study drug . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e . ≤ Grade 1 Baseline ) adverse event ( AEs ) due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 14 day 5 halflives ( whichever longer ) prior study Day 1 recover ( i.e . ≤ Grade 1 Baseline ) AEs due previously administer agent . Has receive transfusion blood product ( include platelet red blood cell ) administration colony stimulate factor within 4 week prior study Day 1 . Has know additional malignancy progress require active treatment . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Has history interstitial lung disease . Has active infection require systemic therapy . Is pregnant breastfeeding , expect conceive father child within project duration study . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B Hepatitis C. Has receive livevirus vaccination within 30 day plan treatment start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>